New Immunotherapy Combination for Advanced Melanoma
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (cadonilimab and interferon) given before surgery to treat advanced melanoma that has spread to nearby lymph nodes or one distant site. The goal is to shrink tumors and improve chances of successful surgery and long-term survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 with confirmed melanoma that is stage III (spread to lymph nodes) or resectable stage IV (one removable distant tumor, no brain tumors)
- No previous treatment with similar immunotherapy drugs (PD-1, PD-L1, CTLA-4 inhibitors), interferon, chemotherapy, or radiation in the past month
- Generally good health (able to be up and about most of the day) with expected survival of at least 6 months
- Normal or near-normal blood counts, kidney, and liver function within 4 weeks before starting treatment
- If female and able to have children: negative pregnancy test and agreement to use contraception for 12 months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This early-phase trial studies a combination treatment—an interferon-type medicine, an immune checkpoint antibody, and a targeted anti-angiogenesis pill—for advanced melanoma that cannot be removed with surgery. The goal is to see whether this combination can shrink tumors and be tolerated, and to learn the best way to treat this stage of melanoma.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
This trial tests a combination of two drugs, cadonilimab and anlotinib, for people with melanoma that has gotten worse or spread after their first treatment. It aims to see if this new combination can help when standard options have stopped working.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.